NCT06395376

Brief Summary

This is a small intervention study which is aimed at characterizing what is known as the adaptive stress response (also know as "hormesis") in women aged 30-45 years. Participants will perform Bikram Yoga in a room heated to 104°F (40°C) which is often referred to as "Hot Yoga". The hypothesis of this study is that a protective and health-promoting adaptive stress response can be induced in living humans by performing exercise in a hot environment. The primary question is:How does the body physiologically adapt to performing moderately vigorous exercise in a hot environment?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 11, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 13, 2023

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2023

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 2, 2024

Completed
Last Updated

May 2, 2024

Status Verified

April 1, 2024

Enrollment Period

3 months

First QC Date

April 24, 2024

Last Update Submit

April 29, 2024

Conditions

Keywords

YogaHyperthermiaInflammationExercise

Outcome Measures

Primary Outcomes (5)

  • Inflammatory biomarkers

    cytokines and hsCRP

    Assessed at baseline, Intervention week1, intervention midpoint (3 weeks), end of intervention (Week 6). end of study (Week 12; after washout)

  • Blood Lipids

    Lipid panel (milligrams per deciliter, mg/dL)

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • Hemoglobin A1C

    Comprehensive Metabolic Panel (millimole per mole, mmol/mol)

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • Fasting glucose/insulin

    Comprehensive Metabolic Panel (milligrams per deciliter, mg/dL)

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • Immune cell phenotypes

    Percent Immune phenotypes

    Measured at the Start of Intervention (Week1), intervention midpoint (Week 3), end of intervention (Week 6), and end of study (Week 12; after washout)

Secondary Outcomes (6)

  • Positive and Negative Affect Schedule (PANAS) (Measures Positive and Negative Mood)

    Assessed at Baseline, Midpoint of Intervention (Week 3), End of Intervention (Week 6) and End of Study (Week 12)

  • PROMIS (Patient Reported Outcomes Measurement Information System) - Global Health Scale (Measures well-being)

    Assessed at Baseline, Midpoint of Intervention (Week 3), End of Intervention (Week 6) and End of Study (Week 12)

  • Warwick-Edinburgh Mental Well-being Scale (WEMWBS) (Measures well-being)

    Assessed at Baseline, Midpoint of Intervention (Week 3), End of Intervention (Week 6) and End of Study (Week 12)

  • Patient Health Questionnaire (PHQ-9) (Measures depression)

    Assessed at Baseline, Midpoint of Intervention (Week 3), End of Intervention (Week 6) and End of Study (Week 12)

  • Generalized Anxiety Disorder (GAD-7)

    Assessed at Baseline, Midpoint of Intervention (Week 3), End of Intervention (Week 6) and End of Study (Week 12)

  • +1 more secondary outcomes

Other Outcomes (5)

  • Changes in body wieght

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • Changes Body Mass Index (BMI) in kg/m^2

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • Changes in waist-to-hip ratio (WHR)

    Measured at Baseline, end of intervention (Week 6), and end of study (Week 12; after washout)

  • +2 more other outcomes

Study Arms (2)

Hot Yoga Intervention

EXPERIMENTAL

Bikram Hot Yoga intervention: Participants perform a minimum of 60-minutes of Hot Yoga (Bikram Sequence), 3x per week in a heated room (40 degrees C) for 6-weeks

Other: Bikram Hot Yoga Intervention

Hot Yoga Washout

OTHER

Hot Yoga Washout: Participants complete a 6-week "Washout" period during which the participants performed no Hot Yoga.

Other: Hot Yoga Washout

Interventions

Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week "washout" period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)

Hot Yoga Intervention

The "Washout" period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga.

Hot Yoga Washout

Eligibility Criteria

Age30 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsProspective participants need to be healthy women aged 30 and 45 years (≥30 years and ≤45 years). Not pregnant or planning to get pregnant, not lactating, not menopausal.
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, non-menopausal women between the aged 30 to 45 years (≥30 years and ≤45 years)
  • Not pregnant/not planning to get pregnant during the study duration
  • Have not previously participated in hot yoga in the last 12-months
  • Able to give informed consent and be willing to participate for the entirety of the study

You may not qualify if:

  • Agree to allow samples to be stored for future use
  • Pass the preliminary health screening
  • Answer no for every question on the Physical Activity Readiness Questionnaire (PAR-Q ) during preliminary screening
  • fasting Triglycerides greater than 150 milligrams/deciliter
  • Blood pressure greater than 130/90
  • Body Mass Index equal to or greater than 30 or less than 19
  • Fasting glucose greater than 125 milligrams/deciliter.
  • Having a pacemaker or a defibrillator 10) Taking any of the following drugs:
  • Taking greater than 100 mg aspirin/day
  • Taking non-steroidal anti-inflammatory drugs or oral corticosteroids
  • Taking monteleukast-type of allergy medications
  • Use of statins, niacin or fibrates or other lipid lowering medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tucson Yoga Sol

Tucson, Arizona, 85704, United States

Location

MeSH Terms

Conditions

InflammationDepressionAnxiety DisordersHyperthermiaMotor Activity

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsBehavioral SymptomsBehaviorMental DisordersBody Temperature ChangesSigns and SymptomsHeat Stress DisordersWounds and Injuries

Study Officials

  • Floyd Chilton, Ph.D.

    University of Arizona

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Department of Nutritional Sciences Director, Precision Nutrition & Wellness Initiative Associate Director,The BIO5 Institute

Study Record Dates

First Submitted

April 24, 2024

First Posted

May 2, 2024

Study Start

February 11, 2023

Primary Completion

May 13, 2023

Study Completion

May 15, 2023

Last Updated

May 2, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations